Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach

PURPOSE: Exacerbations drive outcomes and costs in chronic obstructive pulmonary disease (COPD). While patient-level (micro) simulation cost-effectiveness models have been developed that include exacerbations, such models are complex. We developed a novel, exacerbation-based model to assess the cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakhotia, Bhavesh, Mahon, Ronan, Gutzwiller, Florian S, Danyliv, Andriy, Nikolaev, Ivan, Thokala, Praveen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174156/
https://www.ncbi.nlm.nih.gov/pubmed/32368025
http://dx.doi.org/10.2147/COPD.S247156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174156/
https://www.ncbi.nlm.nih.gov/pubmed/32368025
http://dx.doi.org/10.2147/COPD.S247156

Ejemplares similares